With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally
The $5.4 billion acquisition of Global Blood Therapeutics by Pfizer was sealed with a phone call and a commitment to reach patients with sickle cell disease wherever in the world they live.